| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Entero Therapeutics, Inc. | Director | Common Stock | 24,889 | $105,266 | $4.23 | 11 Jun 2024 | Direct |
| Entero Therapeutics, Inc. | Director | Common Stock | 440 | $1,861 | $4.23 | 11 Jun 2024 | Indirect |
| First Wave BioPharma, Inc. | Director | Stock Option (right to buy) | 52,980 | 13 Mar 2024 | Direct | ||
| First Wave BioPharma, Inc. | Director | Common Stock, par value $0.0001 per share | 440 | 13 Mar 2024 | Indirect | ||
| First Wave BioPharma, Inc. | Director | Series G Non-Voting Convertible Preferred Stock | 141 | 13 Mar 2024 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ENTO | Entero Therapeutics, Inc. | 11 Jun 2024 | 1 | $0 | 4 | Director | 12 Jun 2024, 18:23 |
| ENTO | First Wave BioPharma, Inc. | 13 Mar 2024 | 3 | $0 | 4 | Director | 15 Mar 2024, 18:05 |
| ENTO | First Wave BioPharma, Inc. | 13 Mar 2024 | 0 | $0 | 3 | Director | 15 Mar 2024, 18:00 |